IndustryopenPR.com23h ago
Cell Penetrating Peptide Market Outlook 2026-2033: Size,
Cell Penetrating Peptide Market Outlook 2026-2033: Size, Source: openPR.com Read the full article at the original source for complete details.
Read article
Latest
Peptide News
The latest peptide research news, clinical trial results, and industry updates from trusted sources.
82 articles
IndustryThe Indian Panorama23h ago
Oxytocin: Roles in Neurochemical Signaling and Systems Biology
Oxytocin: Roles in Neurochemical Signaling and Systems Biology Source: The Indian Panorama Read the full article at the original source for complete details.
Read article
IndustryKnoxville News Sentinel23h ago
Verified Peptide Supplier Raises the Bar for Research Labs
Verified Peptide Supplier Raises the Bar for Research Labs Source: Knoxville News Sentinel Read the full article at the original source for complete details.
Read article
Industrystatnews.com23h ago
My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine statnews.com
Read article
ResearchJ Control Release23h ago
Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives.
Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives. Ai D(1), Li J(2), Shi J(1), Sang S(1), Zhang B(1), Ge S(3), Deng S(4). Author information: (1)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. (2)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu, China. (3)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu, China. Electronic address: geshushan0820@163.com. (4)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Electronic address: dshming@163.com. In recent years, the regulatory approval of radiopharmaceuticals such as [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617, alongside their diagnostic counterparts [68Ga]Ga-DOTATATE and [68Ga]Ga-PSMA-11, has propelled theranostics into the clinical mainstream, marking a transformative shift in nuclear medicine and precision oncology. Amid this dynamic progress, cyclic peptides have emerged as indispensable vectors for targeted delivery in nuclear medicine, owing to their exceptional resistance to enzymatic degradation, superior conformational stability, and high receptor-binding affinity. These properties endow radiolabeled cyclic peptides with favorable pharmacokinetics, elevated tumor accumulation, and excellent target-to-background contrast, features that have enabled their widespread application in imaging and therapy targeting somatostatin receptors, integrins, FAP, PD-L1, and other tumor-associated biomarkers. With their molecular precision, structural versatility, and therapeutic adaptability, cyclic peptides are positioned at the forefront of next-generation radiopharmaceutical development. As the field continues to evolve toward increasingly personalized and molecularly targeted cancer therapies, radiolabeled cyclic peptides are poised to play a pivotal role in redefining the future landscape of radiotherapy. Copyright © 2026. Published by Elsevier B.V. Conflict of interest statement: Declaration of competing interest The authors declare no competing interests.
Read article
1 / 17
Peptide news, delivered.
Get the latest research news and industry updates sent to your inbox weekly. No spam, unsubscribe anytime.
For research purposes only. Unsubscribe anytime.